Novartis' Ilaris For Gout: FDA Questions Whether Symptom Relief Is Worth Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will also ask its Arthritis Advisory Committee at a June 21 meeting whether the sponsor should explore lower doses for the interleukin-1 beta inhibitor.
You may also be interested in...
With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.
With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.
Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety
FDA’s review of Novartis’ sBLA for Ilaris (canakinumab) in gout reflects an evolving agency philosophy toward dose optimization for biologic agents – an approach that is likely to require more sponsor attention to pre-approval dose exploration studies.